Provided by Tiger Fintech (Singapore) Pte. Ltd.

NKGEN BIOTECH INC

0.1913
-0.3245-62.91%
Post-market: 0.1900-0.0013-0.68%19:59 EST
Volume:8.44M
Turnover:2.31M
Market Cap:8.60M
PE:-0.04
High:0.5099
Open:0.5099
Low:0.1903
Close:0.5158
Loading ...

Company Profile

Company Name:
NKGEN BIOTECH INC
Exchange:
NYSE
Establishment Date:
2017
Employees:
63
Office Location:
3001 Daimler Street,Santa Ana,California,United States
Zip Code:
92705
Fax:
- -
Introduction:
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.

Directors

Name
Position
Gus Garcia
Co-President and Director
Lewis Silberman
Co-President and Director
A. B. Cruz III
Director
Edwin J. Rigaud
Director
Jeanne L. Manischewitz
Director

Shareholders

Name
Position
James A. Graf
Chief Executive Officer
Anantha Ramamurti
Chief Financial Officer and Treasurer
Anthony A. Kuznik
Executive Vice President, General Counsel and Secretary
Gus Garcia
Co-President and Director
Lewis Silberman
Co-President and Director
Sabrina McKee
Executive Vice President, Strategy